FULC Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Stats
Today's Volume	325 636
Average Volume	574 926
Market Cap	296.75M
EPS	$0 ( 2023-11-14 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.89
ATR14	$0.250 (5.21%)

Insider Trading

Date	Person	Action	Amount	type
2023-08-07	Musso Alan A	Buy	432 800	Stock Option (right to buy)
2023-08-07	Musso Alan A	Sell	0	No securities are beneficially owned
2023-07-01	Sapir Alex	Sell	2 430 400	Stock Option (right to buy)
2023-06-27	Geraghty James A	Buy	30 000	Stock Option (right to buy)
2023-06-27	Haviland Kate	Buy	30 000	Stock Option (right to buy)

INSIDER POWER
11.25
Last 98 transactions
Buy: 8 548 515 \| Sell: 9 114 462

Correlation (AI algo v.1.1b): Undervalued: 0.50% $4.82 paired level. (The Algo Track The Changes Of The Most Correlated Stocks In Realtime And Give An Instant Update)

Volume Correlation

Long: -0.70 (moderate negative)

Short: -0.88 (strong negative)

Signal:(47) Neutral

Fulcrum Therapeutics Inc Correlation

10 Most Positive Correlations
ABST	0.942
SRTS	0.94
MULN	0.929
VNET	0.928
CNDT	0.919
EGAN	0.917
SABRP	0.916
SABR	0.91
DOYU	0.91
PASG	0.907

10 Most Negative Correlations
RDUS	-0.927
XOG	-0.9
TYHT	-0.895
EPZM	-0.881
OPCH	-0.871
SYKE	-0.868
HSTM	-0.864
CNCE	-0.856
CRWD	-0.848
ICON	-0.846

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Fulcrum Therapeutics Inc Correlation - Currency/Commodity

-0.49
( neutral )

-0.63
( weak negative )

0.00
( neutral )

-0.59
( weak negative )

Fulcrum Therapeutics Inc Financials

Annual	2022
Revenue:	$6.34M
Gross Profit:	$6.34M (100.00 %)
EPS:	$-2.35

Q2	2023
Revenue:	$759 000
Gross Profit:	$759 000 (100.00 %)
EPS:	$-0.390

Q1	2023
Revenue:	$880 000
Gross Profit:	$880 000 (100.00 %)
EPS:	$-0.380

Q2	2023
Revenue:	$880 000
Gross Profit:	$880 000 (100.00 %)
EPS:	$-0.380

Fulcrum Therapeutics Inc

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.